Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
Once-a-day highly active antiretroviral therapy in treatment-naive HIV-1-infected adults in Senegal
AIDS, Volume 17, No. 7, Year 2003
Notification
URL copied to clipboard!
Description
Objectives: To study the effectiveness, adherence and tolerance of a once-a-day highly active antiretroviral therapy regimen in adults in Senegal. Design and methods: In a prospective, open-label one-arm study, 40 treatment-naive HIV-1-infected patients took the following three drugs once a day at bedtime: didanosine, lamivudine and efavirenz. The primary endpoint was the percentage of patients with plasma HIV-1 RNA below 500 copies/ml at 6 months. The analysis was done on an intent-to treat basis. Results: Eighty-five per cent of patients were at Centers for Disease Control and Prevention stage B or C and the plasma HIV RNA level was 5.4 ± 0.4 log10 copies/ml at baseline. The percentage of patients with plasma HIV-1 RNA below 500 copies/ml at 6 months was 95% [95% confidence interval (CI), 83-99]. The proportions of patients with plasma HIV-1 RNA below 50 copies/ml at months 3, 6, 9, 12 and 15 were 26% (n = 39; 95% CI, 12-39), 78% (n =40; 95% CI, 65-90), 70% (n = 40; 95% CI, 56-84), 77% (n = 39; 95% CI, 64-90) and 69% (n = 39; 95% CI, 55-84), respectively. The CD4 cell count was 164 ± 75 × 106/l at baseline and increased by a mean of 199 ± 101 × 106/l at month 15. Permanent treatment discontinuation was never necessary for serious adverse effects. Adherence was excellent, as shown by plasma drug concentrations and according to the results of the questionnaire. Conclusions: The once-daily regimen of didanosine, lamivudine and efavirenz was safe, easy-to-take and demonstrated strong antiretroviral and immunologic effects in African patients with advanced HIV infection. © 2003 Lippincott Williams & Wilkins.
Authors & Co-Authors
Landman, Roland
France, Paris
Hôpital Bichat-claude-bernard Ap-hp
Schiemann, Ricarda
France, Paris
Hôpital Bichat-claude-bernard Ap-hp
Thiam, Safiatou
Senegal, Dakar
Fann University Teaching Hospital
Vray, Muriel M.
France, Paris
Inserm
Canestri, Ana
France, Paris
Hôpital Bichat-claude-bernard Ap-hp
Mboup, Souleymane
Senegal, Dakar
Le Dantec University Teaching Hospital
Touré-Kâne, Coumba
Senegal, Dakar
Le Dantec University Teaching Hospital
Delaporte, Éric
France, Montpellier
Ird Centre de Montpellier
Sow, Papa Salif
Senegal, Dakar
Fann University Teaching Hospital
Faye, Mame Awa
Senegal, Dakar
Fann University Teaching Hospital
Guèye, Mandoumbé
Senegal, Dakar
Military Hospital
Peytavin, Gilles
France, Paris
Hôpital Bichat-claude-bernard Ap-hp
Dalban, Cécile
France, Paris
Inserm
Girard, Pierre Marie
France, Paris
Hôpital Saint-antoine
Ndoye, Ibrahima
Senegal, Dakar
National Aids Program
Statistics
Citations: 98
Authors: 15
Affiliations: 8
Identifiers
Doi:
10.1097/00002030-200305020-00010
Research Areas
Infectious Diseases
Study Design
Cohort Study
Study Locations
Senegal